TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Income from Continuing Operations of 28666000.0 for Q1 2026, up 22.49% year-over-year from 23402572.6 in Q1 2025, and up 9.98% quarter-over-quarter from 31844000.0 in Q4 2025.
TScan Therapeutics (TCRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Income from Continuing Operations for 7 consecutive years, with 28666000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 22.49% year-over-year to 28666000.0; the TTM figure through Mar 2026 stood at 133172000.0 (up 8.32% YoY), while the FY2025 annual figure was 219857000.0, down 52.08% from the prior year.
- Income from Continuing Operations rose to 28666000.0 in Q1 2026 per TCRX's latest filing, from 31844000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15097000.0 in Q2 2022 and bottomed at 46733000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 27381647.06 across 5 years, with a median of 28666000.0 in 2026.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 54.13% — and 2024, when it tumbled 130.68%.
- TScan Therapeutics' Income from Continuing Operations stood at 19547000.0 in 2022, then fell by 3.64% to 20259000.0 in 2023, then slumped by 130.68% to 46733000.0 in 2024, then soared by 31.86% to 31844000.0 in 2025, then advanced by 9.98% to 28666000.0 in 2026.
- Business Quant data shows TCRX's Income from Continuing Operations at 28666000.0 in Q1 2026, 31844000.0 in Q4 2025, and 35710000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -30.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.36 Mn |
| Mar 31, 2026 | -28.67 Mn |
| Dec 31, 2025 | -31.84 Mn |
| Sep 30, 2025 | -35.71 Mn |
| Jun 30, 2025 | -36.95 Mn |
| Mar 31, 2025 | -36.98 Mn |
| Dec 31, 2024 | -46.73 Mn |
| Sep 30, 2024 | -29.89 Mn |
| Jun 30, 2024 | -31.66 Mn |
| Mar 31, 2024 | -30.14 Mn |
| Dec 31, 2023 | -20.26 Mn |
| Sep 30, 2023 | -23.00 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -19.55 Mn |
| Sep 30, 2022 | -16.25 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -16.16 Mn |
| Dec 31, 2021 | -14.89 Mn |
| Sep 30, 2021 | -25.29 Mn |